Pilot Study of a Patient Centered Multi-Agent Decision Support System PCM-DSS with Continuous Glucose Monitoring to Manage Type 2 Diabetes Treated with Insulin

What this Trial Is About

Researchers are evaluating a patient-centered decision support system software designed to help healthcare providers manage multi antidiabetic drug therapy for people with type 2 diabetes who use insulin. The study aims to test the safety and feasibility of this software in guiding treatment. This pilot study focuses on adults with type 2 diabetes treated with insulin and receiving multiple diabetes medications. Participants will be randomly assigned to one of two groups. One group will use their personal insulin pen along with a continuous glucose monitor CGM and have their therapy guided by the Patient Centered Multi-Agent Decision Support System PCM-DSS through a TREAT2D Report for 16 weeks. The other group will also use a CGM and their personal insulin pen but receive usual care from their physician for the same 16-week period. Both groups will then complete a 2-week maintenance phase where the therapy established during the intervention phase is maintained. During the study, participants will wear a CGM and adjust their insulin therapy under physician guidance. Data will be uploaded via the internet as needed. Researchers will monitor clinical efficacy over 22 weeks to assess the impact of the decision support system compared to usual care. Safety and feasibility will also be evaluated through ongoing monitoring and follow-up throughout the study duration.

Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers